ESR1 and breast cancer: Correspondingly, screening for overexpression of these factors might lead to early identification of ER+ breast cancer patients at risk for endocrine resistance and help to devise the most suitable therapeutic approaches to minimize the risk and optimize the effectiveness of anticancer treatment.